Excessive Sedation With Depot Zyprexa Can Be Handled In Label, Cmte. Says
Executive Summary
Labeling that restricts use and a risk management plan for the depot formulation of Lilly's Zyprexa (olanzapine) will be enough to balance the risk of excessive sedation associated with the atypical antipsychotic, according to FDA's Psychopharmacologic Drugs Advisory Committee
You may also be interested in...
IFRA Hosts Capitol Hill Scent Experience In Timeout From Policy Concerns
The International Fragrance Association North America took a break from its higher-stakes advocacy work Nov. 1 to give lawmakers and congressional staffers a "scent experience." Perfumers from six of the group's biggest members were on hand with "Scents of Home," joined by Monell Center researchers to educate attendees on the mechanics of scent and the important role it plays in people's lives.
NSF's Cosmetics Verification Program Fizzles, While EWG's Could See Second Boom
NSF International has put its cosmetic product verification program on ice due to lack of interest since its launch in April 2017. Meanwhile, more than 1,000 products from 75+ brands have earned the "EWG Verified" mark, and the NGO says interest is higher than ever following Walmart's announcement in September that it will begin pushing vendors to pursue the verification.
PCPC Appoints Beiersdorf R&D Exec To Chief Scientist Post
Alexandra Kowcz is the Personal Care Product Council's new executive VP for science, effective Jan. 29, 2018. She brings to the trade association extensive experience from R&D and manager roles at Beiersdorf and P&G, as well as drug firms and cosmetic ingredient supplier Centerchem.